AGM
PBYI icon

Alpine Global Management’s Puma Biotechnology PBYI Stock Holding History

Alpine Global Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,116
Closed -$131K – 380
2024
Q2 		$131K Buy
+40,116
New +$176K 0.02% 369
2020
Q1 		– Sell
-51,060
Closed -$447K – 387
2019
Q4 		$447K Buy
+51,060
New +$423K 0.1% 180
2015
Q3 		– Sell
-252
Closed -$29K – 609
2015
Q2 		$29K Buy
+252
New +$45.6K ﹤0.01% 880

Other funds holding PBYI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Alpine Global Management's PBYI Position: Q3 2024 in Review

Alpine Global Management sold out of Puma Biotechnology (PBYI) in Q3 2024, closing a stake of 40,116 shares — an estimated $131K sold.

Alpine Global Management first reported a position in PBYI in Q2 2015 and held it in 3 quarters. The position peaked at $447K in Q4 2019. 100 funds tracked by Wall St. Rank hold PBYI as of Q3 2024.

  • Alpine Global Management reported no remaining Puma Biotechnology position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 40,116 Puma Biotechnology shares in Q3 2024, an estimated $131K.
  • Alpine Global Management first reported a position in Puma Biotechnology in Q2 2015 and held it in 3 quarters.
  • Alpine Global Management's Puma Biotechnology position peaked at $447K in Q4 2019.
  • 100 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.